MX2016017290A - Antagonistas duales de factor de crecimiento derivado de plaquetas (pdgf)/factor de crecimiento endotelial vascular (vegf). - Google Patents

Antagonistas duales de factor de crecimiento derivado de plaquetas (pdgf)/factor de crecimiento endotelial vascular (vegf).

Info

Publication number
MX2016017290A
MX2016017290A MX2016017290A MX2016017290A MX2016017290A MX 2016017290 A MX2016017290 A MX 2016017290A MX 2016017290 A MX2016017290 A MX 2016017290A MX 2016017290 A MX2016017290 A MX 2016017290A MX 2016017290 A MX2016017290 A MX 2016017290A
Authority
MX
Mexico
Prior art keywords
antagonist
pdgf
vegf
pdgfr
vegfr
Prior art date
Application number
MX2016017290A
Other languages
English (en)
Other versions
MX379491B (es
Inventor
Wayne To
Tetsuya Ishino
Lidia Mosyak
Victor Perlroth D
A Charles Stephen
Aggen James
Benoit Didier
Lin Laura
Cohen Justin
Somers William
Original Assignee
Kodiak Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kodiak Sciences Inc filed Critical Kodiak Sciences Inc
Publication of MX2016017290A publication Critical patent/MX2016017290A/es
Publication of MX379491B publication Critical patent/MX379491B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona un antagonista dual de VEGF/PDGF que comprende un antagonista de VEGF enlazado a un antagonista de PDGF. El antagonista de VEGF es un anticuerpo a un VEGF o VEGFR o es un segmento de trampa extracelular de VEGFR (es decir, un segmento de la región extracelular de uno o más receptores VEGFR que inhibe la unión de al menos un VEGFR a al menos un VEGF). El antagonista de PDGF es un anticuerpo a un PDGF o PDGFR o es un segmento de trampa extracelular de PDGFR (es decir, un segmento de la región extracelular de uno o más PDGFR, que inhibe la unión de al menos un PDGFR a al menos un PDGF). El antagonista dual se conjuga preferentemente a una porción de extensión de vida media, tal como un polímero HEMA-PC. El antagonista dual es particularmente útil para tratar degeneración macular húmeda relacionada a la edad.
MX2016017290A 2014-06-28 2015-06-28 Antagonistas duales de factor de crecimiento derivado de plaquetas (pdgf)/factor de crecimiento endotelial vascular (vegf) MX379491B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462018579P 2014-06-28 2014-06-28
PCT/US2015/038203 WO2015200905A2 (en) 2014-06-28 2015-06-28 Dual pdgf/vegf antagonists

Publications (2)

Publication Number Publication Date
MX2016017290A true MX2016017290A (es) 2017-08-24
MX379491B MX379491B (es) 2025-03-10

Family

ID=54938964

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016017290A MX379491B (es) 2014-06-28 2015-06-28 Antagonistas duales de factor de crecimiento derivado de plaquetas (pdgf)/factor de crecimiento endotelial vascular (vegf)
MX2021001160A MX2021001160A (es) 2014-06-28 2016-12-20 Antagonistas duales de factor de crecimiento derivado de plaquetas (pdgf)/factor de crecimiento endotelial vascular (vegf).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021001160A MX2021001160A (es) 2014-06-28 2016-12-20 Antagonistas duales de factor de crecimiento derivado de plaquetas (pdgf)/factor de crecimiento endotelial vascular (vegf).

Country Status (7)

Country Link
EP (1) EP3161000A4 (es)
JP (3) JP7100425B2 (es)
CN (1) CN107428824A (es)
AU (2) AU2015279560B2 (es)
CA (1) CA2953698A1 (es)
MX (2) MX379491B (es)
WO (1) WO2015200905A2 (es)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10363290B2 (en) 2014-10-17 2019-07-30 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
US10702608B2 (en) 2013-09-08 2020-07-07 Kodiak Sciences Inc. Factor VIII zwitterionic polymer conjugates
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
US11155610B2 (en) 2014-06-28 2021-10-26 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US11819531B2 (en) 2009-12-18 2023-11-21 Kodiak Sciences Inc. Multifunctional zwitterionic polymer conjugates
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3411399A4 (en) * 2016-02-04 2019-10-16 Jinsong Ni TECHNOLOGY FOR ANTIBODY-ACTIVE SYNERGISM FOR THE TREATMENT OF DISEASES
US20190204326A1 (en) * 2016-09-27 2019-07-04 The University Of The Highlands And Islands Antigen biomarkers
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
CN110003328B (zh) * 2018-01-05 2022-04-19 百奥泰生物制药股份有限公司 一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
SG11202010178XA (en) * 2018-04-17 2020-11-27 Outlook Therapeutics Inc Buffered formulations of bevacizumab for use of treating diseases
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
JP7119225B2 (ja) 2018-10-05 2022-08-16 ソウル大学校産学協力団 Ｐｄｇｆ受容体に対する抗体およびその用途
EP3891182A4 (en) * 2018-12-03 2022-08-17 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd RECOMBINANT PROTEIN AGAINST PD-L1 AND VEGF
WO2022097065A2 (en) * 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
US20240190943A1 (en) * 2021-03-31 2024-06-13 Hangzhou Exegenesis Bio Ltd. Fusion molecules targeting vegf and angiopoietin and uses thereof
CN116102659A (zh) * 2021-11-11 2023-05-12 三生国健药业（上海）股份有限公司 一种抗il-17/vegf双功能融合蛋白及其用途
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
WO2025042305A1 (ru) * 2023-08-18 2025-02-27 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующпя слитый белок pdgfra-hfc

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
DK1140173T4 (da) * 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
EP2021028A2 (en) * 2006-04-17 2009-02-11 Ludwig Institute For Cancer Research Methods and compositions for modulation of blood-neural barrier
SI2274008T1 (sl) 2008-03-27 2014-08-29 Zymogenetics, Inc. Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102448984A (zh) * 2009-03-27 2012-05-09 酶遗传学股份有限公司 使用包含抗体-受体组合的多特异性结合蛋白的组合物和方法
CN102311502B (zh) * 2010-07-10 2013-12-25 成都康弘生物科技有限公司 一种抑制血管新生或生长的融合蛋白及其医疗应用
US9149427B2 (en) * 2010-12-02 2015-10-06 Neurotech Usa, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
CN102250246A (zh) * 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
WO2013059137A1 (en) * 2011-10-17 2013-04-25 Oligasis High molecular weight zwitterion-containing polymers
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
LT2968461T (lt) * 2013-03-13 2022-12-27 Genzyme Corporation Sulieti baltymai, apimantys pdgf ir vegf surišančius fragmentus, ir jų panaudojimo būdai

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11819531B2 (en) 2009-12-18 2023-11-21 Kodiak Sciences Inc. Multifunctional zwitterionic polymer conjugates
US10702608B2 (en) 2013-09-08 2020-07-07 Kodiak Sciences Inc. Factor VIII zwitterionic polymer conjugates
US11590235B2 (en) 2013-09-08 2023-02-28 Kodiak Sciences Inc. Factor VIII zwitterionic polymer conjugates
US12214044B2 (en) 2013-09-08 2025-02-04 Kodiak Sciences Inc. Factor VIII zwitterionic polymer conjugates
US11155610B2 (en) 2014-06-28 2021-10-26 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10363290B2 (en) 2014-10-17 2019-07-30 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
US11071771B2 (en) 2014-10-17 2021-07-27 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Also Published As

Publication number Publication date
EP3161000A4 (en) 2018-05-02
AU2015279560A1 (en) 2017-01-19
JP2023133585A (ja) 2023-09-22
AU2020286251A1 (en) 2021-01-14
WO2015200905A2 (en) 2015-12-30
WO2015200905A3 (en) 2016-02-18
JP2017526635A (ja) 2017-09-14
AU2015279560B2 (en) 2020-09-17
MX379491B (es) 2025-03-10
JP2021091700A (ja) 2021-06-17
CN107428824A (zh) 2017-12-01
JP7373514B2 (ja) 2023-11-02
JP7100425B2 (ja) 2022-07-13
MX2021001160A (es) 2021-04-19
EP3161000A2 (en) 2017-05-03
CA2953698A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
MX2016017290A (es) Antagonistas duales de factor de crecimiento derivado de plaquetas (pdgf)/factor de crecimiento endotelial vascular (vegf).
CY1124886T1 (el) Χιμαιρικοι υποδοχεις αντιγονου bcma
IL248348A0 (en) Mnd promoter chimeric antigen receptors
IL249305A0 (en) Chimeric antigen receptors targeting cd-19
IL258502A (en) Chimeric antigen receptors targeted to psca
IL251030B (en) Chimeric antigen receptors
PT3362470T (pt) Recetores de antigénios quiméricos que contêm um domínio de clorotoxina
EP3618880A4 (en) PERFUMED ACCESSORY FOR CONTAINERS
CL2016001871A1 (es) Anticuerpos humanos para pd-1
IL261461B (en) Methods of treating depression using orexin-2 receptor antagonists
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
EA201790967A1 (ru) Химерные антигенные рецепторы против cldn и способы их применения
PL3230310T3 (pl) Chimeryczne receptory antygenowe anty-cd70
MX2017006997A (es) Proceso para manipular el nivel de contenido de glicano de una glicoproteina.
IL259947B (en) Heteroarylhydroxypyrimidinones as agonists of the apj receptor
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
PL3107898T3 (pl) 1,2-podstawione cyklopentany jako antagoniści receptorów oreksyn
CY1125153T1 (el) Νεα ετεροκυκλικα αντiοιστρογονα
LT3713928T (lt) Nauji bradikinino b2 receptoriaus antagonistai
DK3334721T3 (da) Cgrp-receptorantagonister
FR3025522B1 (fr) Composition ignifugeante pour substrat textile.
EA201792527A1 (ru) Лечение зуда
EP3733160A4 (en) EMULSIFIED COMPOSITION
TR201401766A2 (tr) Asteninin tedavisine yönelik bir kompozisyon.
TR201401753A2 (tr) Nekroz tedavisine yönelik bir kompozisyon.